Hepatitis B and C viral infections screening in a Tunisian IBD population under immunosuppressive therapies




Palabras clave:

Inflammatory bowel disease, Hepatitis B, Hepatitis C


Background: Immunosuppressive drugs have become a mainstay of therapy for the inflammatory bowel diseases (IBD). These
treatments expose to a risk of hepatitis B and C reactivation. Objective: The aim of this study was to assess the prevalence of hepatitis B and C viruses in Tunisian IBD patients on immunosuppressive treatments. Materials and methods: Patients with inflammatory bowel disease were consecutively recruited over a 2 years period (2017-2018). Prevalence of viral hepatitis B and C as well as clinical, biological and virological presentation, management and outcome were assessed. Factors associated to hepatitis B and C were also analyzed (SPSS software, p value <0.05). Results: Seventy four patients with IBD were included: 38
women and 36 men. Among them 62 (83.8%) had CD and (16.2%) had UC. Mean age was 43.5±14.2 years. Six patients (8.1%) had at least one positive HVB marker. Hepatitis C infection was found in 4% patients. HBs Ag was positive in only one patient (1.3%) with positive HBV DNA. Anti HBc and anti HBs antibodies were positive respectively in 6 and 4 patients. Vaccination against hepatitis B was proposed for 22% of our patients with negative anti HBc antibodies and HBs Ag. Two patients presented non-severe acute hepatitis C with sustained virological response after antiviral treatment. IBD did not relapse under antiviral
treatment. A 3rd patient had chronic hepatitis C infection. She was treated with Pegylated Interferon alpha and Ribavirine. No cases of viral reactivation have been reported. Noassociated factors to hepatitis B and C viral infections were identified in our study. Conclusion: The prevalence of hepatitis B infection in IBD patients under immunosuppressive therapy was similar to the general population, while the hepatitis C prevalence was higher than the national prevalence. Screening for hepatitis B and C
viral infections is mandatory in inflammatory bowel disease patients. Vaccination against hepatitis B is highly recommended.


Los datos de descargas todavía no están disponibles.


Cargando métricas ...




Cómo citar

Sabbah M, Yacoub H, Bellil N, Trad D, Ouakaa A, Elloumi H, Bbani N, Gargouri D. Hepatitis B and C viral infections screening in a Tunisian IBD population under immunosuppressive therapies. Rev Gastroenterol Peru [nternet]. 21 de noviembre de 2020 [citado 10 de junio de 2023];40(3):246-51. isponible en: https://revistagastroperu.com/index.php/rgp/article/view/1124